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Abbreviations: 
Ap = beta amyloid peptide 
AC = Ap cluster 
AD = Alzheimer's disease 
apoE4 = apolipoprotein E4 
APP = amyloid precursor protein 
ASCOM = amyloid surface covering molecules 
BACE = beta-amyloid cleavage enzyme (P-secretase) 
BSA = bovine serum albumin 
ConA = concanavalin-A 
CR = Congo red 
DHE = Dihydro ethidine 
DMEM = Dulbecco's modified Eagle's medium 
DMSO = dimethyl-sulfoxide 
H2O2 = hydrogen-peroxid 
LPYFDn = LPYFD-amide 
MAP2 = microtubule-associated protein 2 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N = neurite 
NAC = non-AI3 component of AD amyloid 
OD = optical density 
P = perikaryon 
PBS = phosphate buffered saline 
pGn = GGGGG-amide 
PIC2 = "Phosphatase Inhibitor Cocktail 2" 
PS-y = presenilin^y-secretase complex 
RA = all-trans-retinoic acid 
RP = rounding perikaryon 
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1. Introduction 
1.1. Characterization of the Alzheimer's disease 
Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, 
Huntington's disease, amyotrophic lateral sclerosis and prion diseases are increasingly realized 
to have common cellular and molecular mechanisms; can be characterized by aggregating 
proteins (Ross at al., 2004), inclusion body formation (Bossy-Wetzel et al., 2004), axon (in 
vivo) and neurite (in vitro) degeneration (Sheetz et al., 1998; Roy et al., 2005), and apoptosis 
(Stoppini et al., 2004). 
AD is mostly a late-onset dementing illness, with progressive loss of memory, task 
performance, speech, and recognition of people and objects (Davison A.N. 1987; Ross et al., 
2004). In AD, neurons of the hippocampus and cerebral cortex are selectively lost. Brains of 
individuals with AD manifest two characteristic lesions: extracellular amyloid (or senile) 
plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protein (Goedert et 
al., 1989; Selkoe, D.J., 2003). Amyloid plaques contain small, toxic cleavage peptides of the 
amyloid precursor protein (APP; 770 amino acids). These peptides consist of 40-42 amino acids 
and called P-amyloid peptides (AP). The alpha-synuclein (major component of Lewy bodies in 
Parkinson's disease) is also present in Alzheimer's amyloid plaques. The toxic cleavage product 
of the alpha-synuclein is the non-AB component of AD amyloid (NAC), which had previously 
been identified as a component of AD amyloid plaques. (Kim et al., 2004; Lavedan, C. 1998; 
Iwai A. 2000) The apolipoprotein E4 (apoE4) genotype is a powerful risk factor for developing 
AD, and it may possibly affect Ap deposition and neurofibrillary tangle formation (Roses, 
A.D., 1996). 
APP is a type I. membrane protein and contains a large extracellular region, a 
transmembrane helix and a short cytoplasmic tail. The N-terminal half of APP contains a 
heparin-binding domain, a copper-binding domain and an APP protease inhibitor domain. 
(Rossjohn, et al., 1999). Toxic Ap originates from regulated intramembrane proteolysis of APP 
by a complex of secretases (Fig. 1.). The first cleavage of APP is mediated by P- or a-secretase, 
releasing most of the extracellular portion of APP as two fragments, APPs-a and APPs-p, 
leaving behind the C-terminal membrane bound fragment. This portion of APP is then cleaved 
by a large protein complex, y-secretase, at several sites including amino acid at 711 (AP 1-40) 
and at 713 (Ap 1-42). The amino acid sequence of the Ap 1-42: 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGWIA 
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In AD, the oxidative stress, the mitochondrial dysfunction and as a result the energy 
deficit may contribute to impaired clearance of protein aggregates and neuronal dysfunction, 
affecting ion channel and pump activity, neurotransmission, and axonal and dendritic transport. 
(Bossy-Wetzel et al., 2004) 
Fig. 1. A model of key events underlying the pathogenesis of AD, based on available evidence. APP molecules on 
the plasma membrane and in intracellular vesicles, such as endosomes, are cleaved by /3-secretase (BACE) and the 
presenilin-y-secretase complex (PS~y) to liberate the Afi A portion of A/l peptides can oligomerize, initially 
intravesicularly, and can be released into the interstitial fluid of the brain, where soluble oligomers may diffuse 
into synaptic clefts and interfere with synaptic function by unknown mechanisms. Afi oligomers can further 
polymerize into insoluble amyloid fibrils that aggregate into spherical plaques, resulting in tortuosity and 
dysfunction of adjacent axons and dendrites. A major accompaniment of such events is the activation of kinases in 
the neuronal cytoplasm, leading to the hyperphosphorylation of the microtubule-associated protein, tau, and its 
polymerization into insoluble filaments (as neurofibrillary tangles). (Dennis J. Selkoe, 2004) 
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1.2. Relations of the in vitro cell breeding techniques and the Alzheimer's disease 
P-Amyloid peptide (AP) aggregates are toxic on neurons (Malouf et al., 1992). Ap 
fibrils also interact with microglial cells and monocytes and stimulate expression of 
proinflammatory genes (Combs et al., 2001). There is a need for an easy and reliable method to 
measure the toxic effects of Ap peptides and similar toxic polypeptide aggregates (e.g. NAC, 
prion peptides, human amylin, etc.). The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay has been widely used to measure the toxicity of different 
substances in cell cultures (Schiff et al., 1985). MTT enters the cells by endocytosis and is 
reduced to formazan by NADH reductase and other enzymes, which can be measured 
spectrophotometrically. All subcellular fractions can reduce MTT when supplied with NADH 
or NADPH. The amount of formazan reflects the reductive potential of the cytoplasm and the 
cell viability. (Liu et al., 1997a) This method has proven to be very useful in neurotoxicity 
studies of AP peptides (Liu et al., 1997b). In most cases, neuroblastoma cells, e.g. SH-SY5Y, 
are applied (Cedazo-Minguez et al., 2001). The MTT assay is rapid and generally shows a good 
correlation with other viability tests (Loske et al., 1998; Soriano et al., 2003) and in vivo results 
(Ghiso etal., 2002; Abe et al., 1998). 
The neurotoxicity of Ap-peptides (Ap 1-42 and Ap 25-35) has been determined with the 
MTT assay on PC-12 (Wei et al., 2000), C 1300 (Takenouchi et al., 1998) and SH-SY5Y 
(Webster et al., 2002) cells. Mostly non-differentiated neuroblastoma cells have been used in 
the MTT assay. Ap and other aggregated peptides (NAC, prions and human amylin) exert toxic 
effect by inducing apoptosis in neuroblastoma cells (Li et al., 1996; Chabry et al., 2003; 
O'Donovan et al., 2001; Rumora et al., 2002). 
Working with non-differentiated cells involves some disadvantages. The number of cells 
is continuously growing during the experiments (e.g. Ap-treatment for 24 h or 48 h), so the 
results of MTT assay ought to be corrected. Yankner et al. reported in 1990 that Ap-peptides 
were neurotrophic to undifferentiated neurons and neurotoxic to mature ones. In cultures, the 
cells are unsynchronized, which means uncertainty in toxicity measurements. The MTT assay 
of AP-peptides might lead to false results when non-differentiated neuroblastoma cells are used, 
because Ap-peptides act mostly on the neurites of the neuroblastoma cells (Kumar et al., 2000; 
Nordin-Andersson et al., 1998). We had the same findings in our experiments. 
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Cell membrane proteins (receptors) play key role in the events that lead to apoptotic cell 
death after Ap treatment. Cell surface receptor complexes are mediating the cellular effects of 
Ap peptides (Bamberger et al., 2003); the membrane composition of differentiated and non-
differentiated cells are different. As a consequence, we have now attempted to improve the 
weak points of the MTT method by using differentiated cells. SH-SY5Y cells were incubated 
with all-iranj-retinoic acid (RA); the resulting differentiated cell culture was used for 
neurotoxicity studies (Lambert et al., 1994). Our aim was to find a reliable in vitro assay for 
neurotoxicity measurements, an MTT assay characterized with two improvements: 1) use of 
highly differentiated neuroblastoma cells which are (morphologically and physiologically) very 
resemble to neurons. 2) Use of constant cell number during the whole experiment; in this case 
the redox activity of the cells is directly proportional to the neurotoxicity of the substances and 
no correction of the results is needed. We wanted to find a method generally suitable for 
measurements of neurotoxicity of very different aggregating peptides like P-amyloids or NAC. 
AD is a synaptic failure caused by the diffusible oligomeric assemblies of the 40-43 
aminoacid-long P-amyloid (Ap; Selkoe, 2002). Ap is neurotoxic (Lambert et al., 1994; Wei et 
al., 2000), induces axonopathy (Higuchi et al. 2002; Terwel et al., 2002) and neuronal 
apoptosis (Loo et al., 1993; Morishima et al., 2001) both in brain tissue (Vickers et al., 2000) 
and in neuroblastoma cells in vitro (Li et al., 1996; Mookherjee et al., 2001). Reliable in vitro 
assays are essential in the investigation of the effects of neurotoxic compounds such as Ap. 
Axonopathy is an early marker of Ap neurotoxicity, in contrast to apoptosis. The measurement 
of neurite degeneration of differentiated SH-SY5Y cells is a useful model for the in vitro 
identification of axonopathy-inducing substances (Nordin-Andersson et al., 1998). 
The axonal disruption induced by Ap is strongly related to the hyperphosphorylation 
and dissociation of the microtubule-associated tau protein (Tomidokoro et al., 2001). The 
phosphorylated tau protein in human cerebrospinal fluid is a diagnostic marker for AD 
(Ishiguro et al., 1999). Tau protein is hyperphosphorylated in human-derived SH-SY5Y cells 
during apoptosis (Mookherjee et al, 2001). This process is essential for Ap-induced 
neurotoxicity (Rapoport et al., 2002): AP amyloidosis evokes the initial stage of tau 
accumulation (Tomidokoro et al., 2001). However, no data has been published so far 
concerning the initial events of the cellular neurotoxicity of Ap, such as the time course of the 
events, the changes in tau phosphorylation and cell viability, and the reversible or irreversible 
character of these changes. 
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In this study, we report the early events of neurite degeneration and intracellular changes 
induced by the 42 aminoacid long peptide (Ap 1-42) in the differentiated SH-SY5Y 
neuroblastoma cell line and the neuroprotective effect of a new pentapeptide, LPYFD-amide 
(LPYFDn). The pentapeptide LPYFDn was designed on the basis of Soto's well-known BSB-
peptide LPFFD (Soto et al., 1998), replacing one of the phenylalanines to tyrosine and the C-
terminal -COO" anion to -CONH2 group. These changes presumably increase the binding 
affinity of the pentapeptide to AP aggregates. Various methods (MTT and Neutral Red 
bioassay, light and fluorescence microscopy, morphological studies, scanning electron 
microscopy, immunocytochemistry and the Congo red (CR) aggregation assay) were used to 
study the neurotoxic events involving Ap 1-42. 
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2. Aims 
Our aim was the in vitro study of the neurodegeneration process, caused by aggregated 
polypeptides and proteins specific for Alzheimer's disease. The following experiments were 
used for modelling the disease in cell cultures: 
1. Use of human neuroblastoma cells has proven to be a good model for neurotoxicity 
studies. However, non-differentiated blastoma cells are not identical with neurons 
containing much less membrane receptors. Our aim was to work out a neurotoxicity test 
using fully differentiated SH-SY5Y human derived neuroblastoma cells; 
2. The exact mechanism of the neurotoxicity caused by aggregated peptides (Ap, NAC) is 
not yet known. Our second aim was searching and modelling of the neurotoxic events 
after treatment of the cells with different aggregating peptides in in vitro cell culture; 
3. During the neurotoxicity process there might be first reversible and after that 
irreversible events. Our third aim was the identification of the irreversibility point (in 
time and cell physiology after treatment with Ap 1-42), which is the critical moment in 
neurodegeneration, because after these event the cell death (apoptosis) is inescapable; 
4. There are already several short Ap-fragments and fragment analogs possessing 
neuroprotective activity against Ap peptides. In our laboratory a series of peptides were 
designed and synthesized. Their protective effects were measured and the best 
pentapeptide (LPYFDn) was intensively studied using different methods. 
On the base of the results of the above summarised experiments a hypothesis for the 
in vitro neurotoxicity of aggregated Ap 1-42 was created. 
We have studied the following hypothetic mechanism of neurodegeneration caused by 
aggregated peptides and proteins: 
Time scale 
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3. Materials and methods 
3.1. Materials 
Ap peptides (1-42, 1-40, 4-42, 5-42, 42-1, 25-35, 31-35, all-D 1-40, MIX 1-42), NAC 
(non-A beta component), LPYFD-amide (LPYFDn), GGGGG-amide (pGn), GRGDS-amide 
(GRGDSn), FRHDS-amide (FRHDSn), KLVFF-amide (KLVFFn) and RIIGL-amide (RIIGLn) 
were synthesized in our laboratory at the Department of Medical Chemistry, University of 
Szeged, Hungary. Solvents were purchased from Merck Europe. Milli-QpLus distilled water was 
used in each experiment. Congo red (CR), Triton 100X, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), Neutral Red, all-irans-retinoic acid (RA), concanavalin-A 
(ConA), bovine serum albumin (BSA), Pluronic acid, Fura-2 AM, Dihydro ethidine (DHE), 
Cl l BODIPY581'591, ethidium bromide, polyclonal antibody pSer396 Anti-Phospho-Tau 
developed in rabbit, mouse monoclonal Anti-Human Amyloid Beta Protein, monoclonal Anti-
MAP2 (2a+2b) antibody produced in mouse, FITC Conjugate-Goat Anti-Rabbit IgG, FITC 
Conjugate-Anti-Mouse IgG and "Phosphatase Inhibitor Cocktail 2" (PIC2) were obtained from 
Sigma-Aldrich (Budapest). 
3.2. Experimental treatments of differentiated SH-SY5Y cells 
The non-differentiated SH-SY5Y cell line was bought from Sigma-Aldrich (Budapest). 
The cells were grown to confluency at 37 °C for 8 days in Dulbecco's modified Eagle's 
medium (MEM):F-12 (1:1) containing phenol red (Sigma-Aldrich; Budapest) on 24- (or 96-) 
well plates (Nunc; Roskilde, Denmark) in a humidified atmosphere containing 5% CO2. L-
Glutamine (4 mM; Gibco; Budapest), penicillin (200 units/ml; Gibco; Budapest), streptomycin 
(200 pg/ml; Gibco; Budapest), MEM non-essential amino acids (Gibco; Budapest), and 10 pM 
all-trans retinoic acid (RA; Sigma-Aldrich; Budapest) were dissolved in DMSO. The final 
concentrations of a\\-trans retinoic acid and DMSO were 10 pM and 0.5%, respectively, and 
10% FBS (Gibco; Budapest) that were added to the medium. On the first day, the number of 
non-differentiated cells in the wells were 2.5 x 10s cells/ml. After 8 days of differentiation, the 
c "5 
cells attached to the plate as a monolayer, and cell counting indicated 3 x 10 cells/cm 
(corresponding to 6.5 x 105 cells/ml in suspension). Before treatment, each peptide was 
ultrasonicated in the culture medium (2% FBS) for 10 min. This medium was free from phenol 
red and differentiating agents (RA, DMSO). The aggregation of Ap peptides were performed in 
14 
aqueous solution (10"5 M) by gentle shaking at room temperature for 24 hours; after aggregation 
the colloidal solution was lyophilized (Fig. 9 shows the fibrillar structure of aggregated AP 
peptides). Differentiated neuroblastoma cells (Datki et al., 2003) were incubated with the 
following peptides: a. 10 pM aggregated AP peptides; b. 10 pM aggregated NAC ; c. a mixture 
of 10 pM aggregated Ap 1-42 and 50 pM LPYFDn; d. 10 pM aggregated Ap 1-42 and 50 pM 
pGn in a 24- (or 96-) well plate for 24, 48 or 72 hours. The original supernatant solution was 
removed from the cells with a pipette and the new medium (1 ml, 2% FBS, 37 °C, containing 
aggregated AP peptides on their own or with the pentapeptides) was added immediately (within 
3 s) to the wells at 37 °C. Sedimented Ap clusters remain cell-bound after washing of the cells 
(Fig. 9/A2). (Paraformaldehyde-fixed cells can not bind AP clusters.) 
3.3. MTT assay using non-differentiated SH-SY5Y neuroblastoma cells 
A slightly modified method of Loske et al (1998) was used in our first experiments. The 
SH-SY5Y cells used here were obtained from Sigma-Aldrich (Budapest). Cells were plated for 
24 h at 37 °C on 96-well plates (Nunc, Roskilde, Denmark) at a density of 3 x 104 cells/well, to 
confluency, with 5% CO2 in a humidified atmosphere with culture medium. Figure 3/A and 4. 
show the short neurites of the non-differentiated cells. 10 pi of aqueous MTT solution (4 
mg/ml) was then added to each well (100 pi), and the mixture was incubated at 37 °C for 3 
hours. The MTT solution was carefully decanted off, and formazan was extracted from the cells 
with 100 pi of a 4:1 DMSO-EtOH mixture in each well. Colour was measured with a 96-well 
ELISA plate reader at 550 nm, with the reference filter set to 620 nm. All MTT assays were 
repeated three times. 
3.4 Improved MTT assay, using differentiated SH-SY5Y neuroblastoma cells 
The same cell culture was used with the following changes: cells were grown for 8-10 
days on 24-(or 96-) well plates, and cell differentiation was initiated by the addition of 10 pM 
RA dissolved in cell culture medium containing 0.5% DMSO. On the first day, the number of 
non-differentiated cells in the wells was 2.5 x 10s cells/ml in suspension. After 8-10 days of 
differentiation, the cells were attached as a monolayer to the plate, and cell counting gave a 
number of 3 x 10s cells/cm2 (corresponding to 6.5 x 10s cells/ml in suspension). Figure 3B 
shows the confluent monolayer of the cells with long neurites (3/C and 4.) and branching 
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neurite terminates (3/D). The supernatant solution was removed with a pipette and a new 
medium (with aggregating peptides, pentapeptides), free from phenol red and differentiating 
agents such as RA and DMSO, was added immediately to each well (within 3 s) at 37 °C. 100 
pi of MTT stock solution (4 mg/ml) was added in each well, containing about 1 ml cell culture 
medium, and the mixture was incubated for 3 hours. The MTT solution was carefully decanted 
off and formazan was extracted from the cells with 1 ml of a DMSO/EtOH (4:1) mixture in 
each well. The color intensity of formazan was measured with a 96-well ELISA plate reader at 
550 nm with the reference filter set to 620 nm. All MTT assays were performed in triplicate; 
one measurement contained 7 parallels (n=21). 
3.5. [3HJ-Thymidine incorporation was measured by the method of Volm et al. (1979). 
3.6. Cell adhesion assay 
Cell adhesion assay was essentially performed as previously described by Luque et al. 
(1994). Differentiated neuroblastoma cells in suspension form were incubated with the 
following peptides: a. anti-integrin.pi antibody (1:100); b. 10 pM aggregated Ap 1-42; c. 10 
pM GRGDSn; d. 10 pM FRHDSn; e. 10 pM KLVFFn; 10 pM RIIGLn and 10 pM LPYFDn in 
Eppendorf tubes for 20 min (Fig. 27). Cells were plated for 2 h at 37 °C on 96-well plates at a 
density of 3 x 104 cells/well, to confluency, with 5% C02 in a humidified atmosphere with 
Dulbecco's modified Eagle's medium (MEM): F-12 (1:1). Nonbound cells were removed by 
rinsing the wells with serum-free medium, whereas bound cells were fixed with methanol, and 
were washed twice with PBS. The cells were stained with 10 pM Cresyl Violet (2 h) and were 
counted per unit area with the aid of an inverted light microscope, using a 20x high-power 
objective and a digital-camera grid (calibrated analysis 3.2 image-computer program). 
Experimental treatments were performed in triplicate with a minimum of three areas counted 
per well, seven wells per cases (n=63). 
3.7. The protein content of the cells was measured with a Lowry assay as modified by Huemer 
etal. (1970). 
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3.8. Monolayer primary neurocyte cultures 
Primary monolayer neurocyte cultures were prepared from rat brain cells, by the 
methods of Sensenbrenner et al. (1984), Durko et al. (1987) and Janka et al. (1980). The 
neurocyte cultures were maintained at 37 °C in humidified atmosphere of 5 % CO2 in air. The 
culture medium was changed in every third day. Cell viability was 90 to 100 %, and the cell 
number was determined as 2 x 105 cells/ml. 
3.9. Morphological evaluation 
In vitro neurite degeneration induced by A|3 1-42 was measured by the morphological 
analysis of the neurites and the cell bodies of differentiated cells (Fig. 12-14). The morphology 
of the neurites (qualitatively complete neurites), according to their thickness and straightness, 
and the morphology of the cell bodies, according to their shape and diameter, were observed. 
Each cell was monitored continuously and photographed every 30 s from 0 min to 60 min 
during the different treatments at 460x magnification. Altogether one hundred cells were 
analyzed. After the treatment, the differentiated cells were fixed with 1% paraformaldehyde for 
20 min, and the nuclei were labeled with ethidium bromide (20 pg/ml) for 10 min in a 1:5 
mixture of DMSO/EtOH. The number and localization of the labeled nuclei were matched the 
number and localization of the cell bodies analyzed morphologically. Measurements were 
performed with a light-fluorescence inverted research microscope (OLYMPUS, Europe). 
Photographed images were analyzed by means of the analySIS 3.2 image-computer program 
(OLYMPUS, Budapest). 
3.10. Scanning electron microscopy 
The amyloid treated SH-SY5Y cells were washed twice with serum free medium (37 
°C) and fixed for 1 h in 1% paraformaldehyde on glass coverslips. Cells were washed with PBS 
(phosphate buffered saline), and dehydrated by successive incubations in 10,30, 50,70 and 
90% ethanol for 10 min, followed by the incubation in 100% ethanol for 5 min 3 times, and in 
acetone for 30 min. Dehydration was completed by drying the coverslips in a desiccating 
chamber. Coverslips were sputter-coated with gold/palladium and imaged using a HITACHI 
S2400 scanning electron microscope. 
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3.11. Measurement of the time-dependent binding of aggregated Af3 on the cells 
After a definite duration (0, 2, 5, 10, 20, 30 on 60 min) of treatment of differentiated 
cells with aggregated Ap 1-42 (10 pM solution) in a 24-well plate, the well content (1 ml) was 
removed and the wells were washed twice with PBS (1 ml/well, 37 °C). The residual 
aggregated Ap-cell complex was suspended in 0.5 ml of PBS (pH=7.4, 37 °C) and 10 pi CR 
(0.5 mM solution) was added to each probe and the mixture was left for 10 min. In order to 
remove unbound CR, solutions were centrifuged twice for 10 min at 5000 and 8000 g. The 
supernatant was removed carefully with a pipette and the sediment was resuspended in PBS 
(0.5 ml/probe). The CR content of the cell-Ap suspension was measured photometrically at 492 
nm (free CR) and 550 nm (bound CR) with an ELISA plate reader (Klunk et al., 1999). The CR 
content of the suspension correlates to the amount of Ap bound to the cell surface. 
3.12. Immunocytochemistry 
3.12.1 Hyperphosphorylated tau protein identification: differentiated neuroblastoma cells 
were incubated with the following peptides: a. 10 pM aggregated Ap 1-42; b. a 
mixture of 10 pM aggregated Ap 1-42 and 50 pM LPYFDn; c. 10 pM aggregated 
AP 1-42 and 50 pM pGn in a 24-well plate for 24 hour. The cells were fixed at room 
temperature by successive applications of 1% paraformaldehyde (10 min), 100% 
methanol (1 min) and again 1% paraformaldehyde (20 min). The wells were washed 
twice with 2% BSA/PBS (2 x 20 min) and PBS (1 ml/well). The polyclonal antibody 
pSer396 Anti-Phospho-Tau developed in rabbit (1:100 dilution) was added to the 
fixed cells, and the mixture was incubated overnight. The primary antibody was 
visualized by labeling with FITC Conjugate-Goat Anti-Rabbit IgG, used at a 
dilution of 1:60 for 4 hours. Controls (lacking primary antibody) had no detectable 
fluorescence. The primary antibody was tested for the positive activity of 
Phosphatase Inhibitor Cocktail 2 (a 1:25 dilution in cell culture medium with 2% 
FBS) via the hyperphosphorylated tau accumulation in the cells. Digital images were 
photographed (Fig. 19) and analyzed (for details see Image Analysis). 
3.12.2 Extracellular A(3 1-42 identification: differentiated neuroblastoma cells were treated 
with the aggregated Ap 1-42 (10 pM) in a 24-well plate for one hour. The wells 
were washed twice with cell culture medium (37°C). The cells were fixed at room 
temperature by successive applications of 4% formaldehyde (30 min). The wells 
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were washed twice with 2% BSA/PBS (2 x 20 min) and PBS (1 ml/well). The 
mouse monoclonal Anti-Human Amyloid Beta Protein (clone: 4G8; 1:100 dilution) 
was added to the fixed cells, and the mixture was incubated overnight. The primary 
antibody was visualized by labeling with FITC Conjugate-Anti-Mouse IgG, used at 
a dilution of 1:100 for 2 hours. Controls (lacking primary antibody) had no 
detectable fluorescence. Digital images were photographed (Fig. 18.A.B.) and 
analyzed. 
3.12.3 MAP2 (microtubule-associated protein 2) identification: differentiated 
neuroblastoma cells were treated with aggregated Ap 1-42 (10 pM) in a 24-well 
plate for 24 hours. The cells were fixed at room temperature by successive 
applications of 4% formaldehyde (30 min). After fixation the cells were treated with 
0.1 % detergent, Triton 100X (10 min). The wells were washed three times with 2% 
BSA/PBS (3 x 20 min) and PBS (1 ml/well). The monoclonal Anti-MAP2 (2a+2b) 
antibody produced in mouse (1:200 dilution) was added to the fixed cells, and the 
mixture was incubated overnight. The primary antibody was visualized by labeling 
with FITC Conjugate-Anti-Mouse IgG, used at a dilution of 1:100 for 4 hours. 
Controls (lacking primary antibody) had no detectable fluorescence. Digital images 
were photographed (Fig. 18.C.D.) and analyzed (for details see Morphological 
evaluation). 
3.13. Neutral Red assay 
The active uptake of a hydrophilic dye was measured by the method of Loske et al. 
(1998). 
3.14. Congo red (CR) aggregation assay 
A modification of the method of Klunk et al. (1999) was used. The aggregated Ap 1-42 
(10 pM) was incubated alone and in other experiments with the different pentapeptide amides 
(LPYFDn or pGn, at 50 pM final concentration) in 1 ml of PBS, pH=7.4, at 37 °C. After 
incubation (aggregation) periods of 5 and 24 hours, 10 pi of CR (0.5 mM) was added to each 
tube (1 ml) and the mixture was incubated for 10 min. Solutions (1 ml) were centrifuged twice 
for 10 min at 5000 and 8000 g. The supernatant was removed carefully with a pipet and the 
sediment was resuspended in PBS (0.5 ml/sample). The CR content of the aggregated peptide-
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CR suspensions was measured photometrically at 492 nm (free CR) and 550 nm (bound CR) 
with an ELISA plate reader. 
3.15. Oxidative stress measuring 
3.15.1 Superoxid level measurement: A modification of the method of Misonou et al. 
(2000) was used. Differentiated neuroblastoma cells were incubated with the 
following peptides: a. 10 pM aggregated Ap 1-42; b. a mixture of 10 pM aggregated 
Ap 1-42 and 50 pM LPYFDn in a 24-well plate for 1-5 hours. The superoxid 
generator paraquat (1 mM) was the positive control, then the cells were fixed at 
room temperature by successive applications of 1% paraformaldehyde (10 min), 
100% methanol (1 min) and again 1% paraformaldehyde (20 min). The wells were 
washed twice with PBS (1 ml/well). Cells were incubated for 30 min at room 
temperature with dihydro-ethidine (DHE; 5 pM) in PBS. Digital images were 
photographed (Fig. 22) and analyzed (see Image analysis). 
3.15.2 Lipid peroxidation measurement: A modification of the method of Pap et al. (1999) 
was used. Differentiated neuroblastoma cells were treated with 10 pM aggregated 
Ap 1-42 in a 24-well plate for 0 or 3 hours. The hydrogen-peroxid (H2O2; 100 pM) 
was the positive control. After treatment, time cells were incubated for 20 min at 
37°C with CI l-BODIPY581/591 (1 pM) in growth medium. Digital images were 
photographed (Fig. 23) and analyzed (see Image analysis). 
3.16. Intracellular calcium level ([Ca2+]i) measurement 
A modification of the method of Laskay et al. (1997) was used. Differentiated 
neuroblastoma cells were treated with 0.02 % Pluronic acid (5 min), washed twice with culture 
medium, 5 pM Fura-2 AM for 30 min at 37 °C. For treatment, the following peptides were 
used: a. 10 pM aggregated Ap 1-42; b. a mixture of 10 pM aggregated Ap 1-42 and 50 pM 
LPYFDn in a 24-well plate for 300 sec. Images were taken with a F-View camera (with CCD 
arrays of 1300 x 1030 pixels). These cameras were interlocked with the imaging system of an 
OLYMPUS 1X71 inverted research fluorescence microscope (640x). The objective table of the 
microscope could be heated up to 37 °C. After the descending line of AP effect the cell activity 
was tested for the positive effect of Ionomycin (30 pM) on the intracellular calcium level. 
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3.17. TEM-experiments 
AP 1-42 was dissolved to a concentration of 115 pM in distilled water by constant 
pipetting for 2 min at 4 °C, followed by a sonication for 10 minutes. Then the solution was 
diluted to a final concentration of 10 pM and incubated for 24 hours at 37 °C. According to the 
method of Walsh et al., 10 pi droplet of the peptide solution was adsorbed to a carbon-coated 
copper grid (Electron Microscopy Sciences, Washington, PA) for 2 min. Then, the droplet was 
replaced with an equal volume of 0.5% (v/v) glutaraldehyde solution and was incubated for an 
additional 1 min. Then, the grid was washed with three droplets of water, followed by an 
incubation of a 10 pi droplet of 2% (w/v) uranyl acetate solution for 2 min. Specimens were 
studied using a Philips CM 10 transmission electron microscope at 100 kV, routinely at 
magnifications of ><46,000 and x64,000. 
3.18. Image analysis 
Images were taken with a 12-bit digital F-View camera (with CCD arrays of 1300 x 
1030 pixels) and a DP 70 color camera. These cameras were interlocked with the imaging 
system of an OLYMPUS 1X71 inverted research fluorescence microscope (640x). Five images 
for each peptide and peptide mixture (see MTT bioassay) at different treatment durations 
(minutes or hours) were subjected to histogram analysis with the analySIS 3.2 and DP 70-BSW 
01.01. image-computer program from OLYMPUS (Europe). Five intensity bins were summed 
for each peptide after each treatment time period to obtain the graphs. 
3.19. Statistical analysis 
ANOVA Post Hoc Test and subsequently Bonferroni and Dunnett t (2-sided) were used 
for statistical calculation with SPSS 9.0 for Windows. Neurotoxicity measurement experiments 
were performed triplicated, unless specified. Each measurement contained 7 parallel treatments 
(wells). When the differences were significant at p<0.01 the values were considered statistically 
significant. The differences were compared to untreated control values. 
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4. Results 
4.1. Differentiation and characterization of the SH-SY5Y human neuroblastoma cell culture 
In the modelling of the AD specific neurodegeneration and neuroprotection in cell 
cultures, we used different types of cells (Fig. 2): non differentiated and/or differentiated human 
derived SH-SY5Y neuroblastoma cells and primary neurocyte cultures from rat brain. The 
fastness and simplicity were the main focuses in the methodologies. The differentiated 
neuroblastoma cells have relatively long neurites (aprox. 270 pm), similarly to the primary 
neurons (Fig. 5). Treatment of SH-SY5Y cells with RA (10 pM) dissolved in DMSO (with 0.5 
% final concentration in the medium) results in the formation of differentiated SH-SY5Y cells. 
These cells display only a slight [ H]-thymidine incorporation increase (Figure 2) and a minor 
protein content change in response to the mitogenic effect of ConA, similarly as for the primary 
neurocyte culture (Figure 5). In contrast, the non-differentiated cells exhibit a extremely 
increased [3H]-thymidine incorporation and protein content after the addition of ConA. The 
response of the differentiated SH-SY5 Y cells to the mitogenic substance is time-dependent: 8 to 
10 days of treatment with RA seems to be enough for appropriate differentiation. Cell culture 
medium does not contain DMSO during AP treatment, therefore, the membrane structure is not 
disturbed by the presence of any organic solvents. 
Figure 6 demonstrates that the cell number in a differentiated SH-SY5Y culture 
becomes stabilized in 6-8 days. In neurotoxicity studies, no correction (e.g calculating of the 
results to protein content) is necessary, if differentiated cells with a constant cell number are 
used. 
Aggregating AP peptides induce neurodegeneration in SH-SY5Y neuroblastoma cells 
(Lambert et al., 1994). Figure 8 illustrates the neurotoxic effects of Ap 1-42 on SH-SY5Y and 
differentiated SH-SY5Y cells (8-day-differentiation). While the non-differentiated SH-SY5Y 
cell number was increased by 70% during a 2-day treatment, the differentiated cell culture 
displayed a constant cell number (control experiments). As a consequence, no correction is 
needed when Ap 1-42 neurotoxicity is measured with the MTT assay on differentiated SH-
SY5Y cells. On the other hand, in work with SH-SY5Y cells, the redox activities (OD of 
soluble formazan) should be corrected by calculation according to the starting cell number 
(100%). 
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Fig. 2. Different cell cultures. A) Non-differentiated SH-SY5Y neuroblastoma cells; B) Differentiated SH-SY5Y 
neuroblastoma cells in confluent monolayer form; C) Differentiated SH-SY5Y neuroblastoma cells in sparsely 
proliferated form; D) Neurites and neurit terminates of SH-SY5Y neuroblastoma cells (arrows); E) Rat neurocytes 
in sparsely form; F) Identification of the neurocytes by anti MAPI antibody (arrows). 
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Fig. 3. The effects of retinoic acid (RA) on cell proliferation detected by thymidine incorporation. (D0: non-
differentiated, control SH-SY5Ycells confluent monolayer; Dfi: SH-SY5Y + 10 pM RA, 6-days; Ds: SH-SY5Y + RA, 
8-days; Dw: SH-SY5Y + RA, 10-days). Mitogen: 0.1 pg/ml ConA for 22 hours, without differentiating agents. 
*DiJferences compared to untreated control values (Dq) are significant at p<0.01, n=21 ; ANOVA Post Hoc Test, 
Dunnett t (2-sided). 
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Fig. 4. The effects of retinoic acid (RA) on cell protein content. (D0: non-differentiated, control SH-SY5Y cells 
confluent monolayer; D6: SH-SY5Y + 10 pM RA, 6- days; Ds: SH-SY5Y + RA, 8-days; D,0: SH-SY5Y + RA, 10-
days). Mitogen: 0.1 pg/ml ConA for 22 hours, without differentiating agents. * Differences compared to 
untreated control values (Dq) are significant at p<0.0l, n=21; ANOVA Post Hoc Test, Dunnett t (2-sided). 
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Fig. 5. Differences in the length of neurites of different cell types in culture. The differentiated SH-SY5Y cell type 
has the longest neurites. * Differences compared to non-differentiated cells are significant at p<0.01, n=100; 
AN OVA Post Hoc Test, Dunnett t (2-sided). 
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Fig. 6. Changes in cell proliferation during the first 8-days of the differentiation process, as measured with MTT 
assay. After treatment with RA, the cell number was increased and in 8 days stabilized. The initial cell number was 
chosen to be 2.5 x 10s/ml in order to reach the monolayer state and maximal cell differentiation in the same time. * 
Differences compared to untreated control values (1-day) are significant at p<0.01, n=21; ANOVA Post Hoc Test, 
Dunnett t (2-sided). 
25 
I u «3 
8 
200 
180 -
1(30 
140 -
120 -
100 
8 0 
(30 -
4 0 
20 -
0 
24 4 8 
I n c u b a t i o n t i m e a f t e r a m y l o i d add i t i on (h) 
S H - S Y 5 Y 
- - • - - D i f f e r e n t i a t e d S H - S Y 5 Y 
— * 2 0 m i c r o M A B 1 ^ » 2 / S I £ S Y 5 Y 
- - x - - 2 0 m i c r o M A B l - 4 2 / D i f f e r e n t i a t e d S H - S Y 5 Y 
Fig. 7. MTT assay of non-differentiated (full line) and 8-day-differentiated SH-SY5Y cells (dotted line), without 
treatment and after treatment for 24 or 48 hours with 20 pM Af 1-42. (In consequence of the increasing number of 
non-differentiated cells, the values are calculated relative to the original cell number). * Differences compared to 
untreated control values (I day) are significant at p<0.01, n=21; ANOVA Post Hoc Test, Dunnett t (2-sided). 
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Fig. 8. Neurotoxic activities for 24 hours of aggregated peptides on differentiated cells, measured with MTT assay. 
* Differences compared to untreated control values are significant at p<0.01, n=21; ANOVA Post Hoc Test, 
Dunnett t (2-sided). 
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Fig. 9. Electron micrograph of Af! 1-42 fibrils formed in a 10 pM peptide solution after 24 hours of incubation at 
37 °C (uranyl acetate background): A/1) A/3 1-42 (1-day aggregation); A/2) aggregated A/3 1-42 clusters bound to 
cells (scanning electron microscopy, bar represent 2 pm). According to Congo red staining, the bright spherical 
clusters are A/3 1-42 aggregates (light microscopical control); B) A/3 1-40 (6-day aggregation); C) A/3 4-42 (8 day 
aggregation) ; D) A/3 5-42 (8- day aggregation). 
4.2. Measuring the neurotoxicity of different aggregated peptides on differentiated SH-SY5Y 
neuroblastoma cells 
The cell biology of Alzheimer's disease is characterized by neurodegeneration caused 
by the p-amyloid (Ap) peptides (Smith et al., 2002). We used differentiated SH-SY5Y cells (8-
day-differentiation) to measure the neurotoxic effect of different AP-peptides and alpha-
synuclein fragments (ex. NAC) in the MTT assay (Figure 9). AP 1-42 aggregated rapidly, 
therefore, it was always aged for 1 day; the other peptides needed a longer (6-8 day) aging time 
(Fig. 9). 10 pM AP 1-42 decreases the redox activity of the cells to 50%. AP 1-40 is also 
neurotoxic at 10 pM, but it causes a smaller decrease of redox activity. The reverse peptide 
structure (Ap 42-1) exhibits only a very small tendency to aggregation and shows no significant 
toxicity. Interestingly, the reverse peptide Ap 35-25 shows some neurotoxic effects. The 
applied NAC reveal high tendency to aggregation and high neurotoxicity. 
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4.3. The neurotoxicity of aggregated A /? 1-42 is time and dose dependent 
We have found that the effect of aggregating Ap 1-42 to the cell viability (measured 
with MTT and Neutral Red assay) is time and dose dependent. Ten pM peptide concentration 
and 24 hours treatment is necessary for 50 % decrease in cell viability. Therefore, we used these 
two parameters. 
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Fig. 10. The toxic effect of Aß 1-42 on differentiated SH-SY5Y cells. Neuroblastoma cells were treated for 24 and 
72 hours with aggregated Aß 1-42 (10 juM). The effect of Aß 1-42 on cell viability (measured with MTT and 
Neutral red assay) was time dependent. * Differences compared to the untreated control values are significant at a 
levelp<0.01, n=21. Statistical analysis by ANOVA post hoc test, Bonferroni. 
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Fig. 11. The toxic effect of Aß 1-42 on differentiated SH-SY5Y cells. Neuroblastoma cells were treated with 
different concentrations of aggregated Aß 1-42 (0.1, 1, 10 and 100 pMfor 24 hours). The effect of Aß 1-42 on cell 
viability (measured with MTT and Neutral red assay) was dose dependent. * Differences compared to the 
untreated control values are significant at a level p<0.01, n-21. Statistical analysis by ANOVA post hoc test, 
Bonferroni. 
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4.4. Exogenous AP1-42 induces in vitro neurite degeneration in d i f f . SH-SY5Y cells 
In vitro experiments serve to model the pathophysiological A(3 accumulation on the 
surfaces of the neurons. The SH-SY5Y neuroblastoma cells possess highly developed neurites 
and exhibit high sensitivity against Ap. Morphological changes could be observed on the cells 
during Ap 1-42 treatment (Fig. 12). Aggregated Ap 1-42 clusters bound strongly to the cells: 
diffusion was unable to remove them from the cells. Aggregated Ap 1-42 bound mainly to the 
lamellipodia and the edge of the perikaryon. Two main morphological changes were observed 
during treatment. The neurites of treated cells became rougher and thinner than those of the 
untreated cells. This was a time-dependent process, very characteristic within 1 h (Fig. 13). The 
vanadate containing phosphatase inhibitor cocktail 2 (in 1:25 dilution) was the positive control. 
Contraction (rounding-off) of the perikaryon was the other main morphological change. This 
was also a time-dependent process which took place within 2 hours. The morphological 
changes, which occured during Ap treatment, were examined more exactly by scanning electron 
microscopy (Fig. 9/A2). This confirmed that the Ap 1-42 clusters bind to the cell surface. After 
24 hours of treatment with 10 pM Ap 1-42, the microtubular system was disintegrated (Fig. 
18/C and 18/D). 
No significant change in cell morphology was observed when AP 1-42 was co-
aggregated with the pentapeptide LPYFDn for 24 hours before treatment (Fig. 14). 
4.5. Exogenous Ap 1-42 decreases the cell viability in differentiated SH-SY5Y cells 
The MTT (redox state) and Neutral Red (active membrane uptake) assays provide 
information about the viability of the cells. Figure 16 demonstrates that aggregated Ap 1-42 
significantly decreases the redox potential of the cells (MTT-assay; Datki et al., 2003). This 
effect of the Ap 1-42 is time (Fig. 10) and dose (Fig. 11) dependent. Vanadate (PIC2) also 
decreases the cell viability to 40%. The pentapeptide LPYFDn itself is not toxic and at 50 pM 
prevents the toxic effect of Ap 1-42 aggregates almost perfectly. In a similar experiment, pGn 
has practically no protective effect. 
Recovery of the cells after Ap 1-42 treatment was also studied by using different 
duration of treatments (Fig. 16). Although the cell culture medium, containing AP 1-42 
aggregates, were thoroughly removed from the cells; a short (2-min) treatment of the cells 
resulted in a significant decrease of the cell viability. (Extensive washing can not remove the 
membrane-bound Ap aggregates perfectly, see Fig. 9/A2). 
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Fig. 12. Cells were incubated with 10 pM aggregated Aft 1-42 for 160 min. Pictures were photographed with a 
light-fluorescence inverted research microscope equipped with a CCD camera at 460x magnification. The cell 
morphology changed dramatically (AC = A ft cluster; N = neurite; P = perikaryon; RP = rounding perikaryon). 
• 10 microM beta-amyloid 1 4 2 Time (min) 
— • 10 imcroM beta-amyloid 1 4 2 + 50 uM LPYFDn 
— * — 50 microM LPYFDn 
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Fig. 13. Decrease in the number of neurites in differentiated SH-SY5Y cells caused by aggregated Aft 1-42 (10 
pM). The vanadate containing phosphatase inhibitor cocktail 2 (in 1:25 dilution) was the positive control. Afi 1-42 
causes neurite degeneration in the first 20 min after treatment. The pentapeptide LPYFDn significantly prevent the 
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neurite degeneration caused by the aggregated Ap 1-42. * The differences in the number of the complete neurites 
per cell body, compared to the LPYFDn alone are significant at a level p<0.01; n=100 in the ANOVA post hoc 
test, Bonferroni. 
Fig. 14. SH-SY5Y cells were incubated with 10 pM Afl 1-42 together with 50 pM LPYFDn pentapeptide for 60 
min. These two peptides were pre-aggregated together for 5 min and/or 12 hours. Pictures were photographed 
with a light-fluorescence inverted research microscope equipped with a CCD camera at 460x magnification (bar 
represents 20 pm). The cell morphology did not change dramatically. 
The longer the duration of AP treatment, the lower the cell viability. The results in Fig. 16 
reveal that treatment with Ap 1-42 for 2 min causes irreversible changes in the cells; even 
recovery for 24 hours was unable to completely restore cell viability. 
Fig. 15. The effect of Aft 1-42 and short pentapeptides on cell viability. Cell viability was detected by means of the 
MTT assay on SH-SY5Y cells. The aggregated Afl 1-42 (10 pM) significantly decreased the cellular redox 
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potential. The vanadate-containing phosphatase inhibitor cocktail 2 (1:25 dilution) was also toxic. The 
pentapeptide LPYFDn is not toxic and at 50 pM prevents the toxic effect of Ap 1-42. pGn can not prevent the 
decrease in the redox potential caused by A f 1-42. * Differences compared to the untreated control values are 
significant at a levelp<0.01, n=21. * Differences compared to the A f 1-42 values are significant at a levelp<0.01; 
n=21. Statistical analysis by ANOVA post hoc test, Bonferroni. 
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Fig. 16. The toxic effect of Ap 1-42 on differentiated SH-SY5Y cells after a short treatment and recovery for 24 
hours. Neuroblastoma cells were treated with aggregated AP 1-42 (10 pM) from 0 to 60 min. After the treatment, 
the cell culture medium, containing Ap, was removed and the cells were washed with new cell culture medium. The 
living cells were incubated for recovery in culture medium (24 h, 37 °C and 5% C02 without Ap). Cell viability 
(measured with MTT and Neutral red assay) decreased irreversibly in the cells after A P 1-42 treatment for 2 to 60 
min. * Differences compared to the untreated control values are significant at a level p<0.01, n=21. Statistical 
analysis by ANOVA post hoc test, Bonferroni. 
4.6. The binding of exogenous Aft 1-42 to differentiated SH-SY5Y celts is a time-dependent 
process 
The optical densities (ODs) measured at 550 nm (A|3-bound CR) correlate with the 
amount of Ap bound to the cell membranes (Klunk et al., 1999). Figure 18 reveals that the 
binding of Ap 1-42 aggregates (10 pM) to the cell membranes depends on the duration of time. 
The binding capacity of the cells is saturable, reaching its limit in 60 min. Neurites are the 
critical part of the neuroblastoma cells (Fig. 18/A and 18/B). After 24 hours treatment with 10 
pM AP 1-42, the microtubular system was disintegrated (Fig. 18/C and 18/D). The visualized 
microtubule-associated protein 2 (MAP2) is specific to the neurons and neuroblastoma cells. 
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Fig. 17. The lime dependence of Afl 1-42 binding to differentiated SH-SY5Y cells. Differentiated SH-SY5Y cells 
were treated from 0 to 60 min with A ft 1-42 (10 pM) aggregated for 1 hour. The supernatant was removed from 
each well after treatment; the cells were fixed with 1% paraformaldehyde and stained with 10 pM Congo red 
(CR). The CR-stained Afi content increased time-dependently. The optical density (OD) of amyloid-bound CR (550 
nm; Klunk et al., 1999) reflects the amount of Afl adsorbed on the cell membrane surface. * OD differences 
(compared to the values at 0 and 2 min) are significant atp<0.01, n-10 (statistical analysis: ANOVA post hoc test, 
Bonferroni). 
Fig. 18. The immunocytochemistry of differentiated SH-SY5Y neuroblastoma cells. A) and B) Cells were incubated 
with 10 pM aggregated Ap 1-42 for 1 hour. The Afi 1-42 (identified with anti-amyloid antibody) binds to the 
surface of the cells (cell bodies, neurites; arrows). C) MAP2 immunocytochemistry. D) Cells were incubated with 
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10 pM aggregated A (3 1-42 for 24 hours. The cell morphology changed dramatically, the microtubule system was 
deorganized. Pictures were photographed with a light-fluorescence inverted research microscope equipped with a 
CCD camera at 460x magnification (bar represents 20 pm). 
4.7. Exogenous A¡31-42 increases tau hyperphosphorylation in differentiated SH-SY5Y cells 
Ap 1-42 is known to cause the significant hyperphosphorylation of tau proteins (Fig. 19; 
Mookherjee et al., 2001). Figure 20 shows that this process reaches its maximal value in the 
Ap-treated cells within 30 min. (When the phosphatase activity was inhibited with a vanadate-
containing cocktail, the amount of hyperphosphorylated tau proteins increased: the shift of the 
phosphorylation-dephosphorylation equilibrium resulted in the formation of 
hyperphosphorylated tau proteins. Vanadate ion is analogous with phosphate ion possessing a 
very similar structure and inhibiting the activity of phosphatases in competitive way). 
The pentapeptide LPYFDn decreased tau hyperphosphorylation (Fig. 20, co-treatment with AP 
1-42). In another experiment, co-treatment of the cells with Ap 1-42 and pGn resulted in the 
same increase of hyperphosphorylation as that due to Ap 1-42 alone (not shown in Fig. 20). 
Fig. 21 shows that the first 10 min of Ap 1-42 treatment causes reversible intracellular tau 
hyperphosphorylation: the washing-out of unbound Ap enables the cells to recover almost 
completely. However, the amount of hyperphosphorylated tau proteins remained high after 
treatment with Ap 1-42 for 20, 30 or 60 min, and after washing and recovery for 24 hours (48 
and 72 hours periods for recovery showed practically no difference compared to the results after 
24 hours). This shows that the biochemical processes initiated by Ap treatment in neuronal cells 
become irreversible after 10 min. 
Fig. 19. The accumulation of hyperphosphorylated tau protein in differentiated SH-SY5Y cells (arrows) labelled 
with pSer396 polyclonal antibody after 30 min of A/3 1-42 treatment. Primary antibody was visualized by labelling 
with FITC-conjugated secondary antibody. Digital images were photographed. 
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Fig. 20. Increase in tau hyperphosphorylation in differentiated SH-SY5Y cells caused by aggregated Aft 1-42. Tau 
hyperphosphorylation was detected with FITC-labeled antibodies. Aggregated Aft 1-42 (10 pM) increased the 
fluorescence intensity significantly during the first 20 min after Aft treatment. The vanadate containing 
phosphatase inhibitor cocktail 2 (a 1:25 dilution) was the positive control: the inhibition of phosphatases (and the 
activation of kinases by Aft 1-42) causes tau hyperphosphorylation in the first 10 min after treatment. The 
pentapeptide LPYFDn significantly inhibits tau hyperphosphorylation caused by the aggregated Aft 1-42. * The 
differences in the fluorescence intensity compared to the untreated control values (0 min) are significant at a level 
p<0.01. "The Fluorescence intensity differences compared to the Aft 1-42 values are significant at a levelp<0.01; 
n=5 (five histograms for each peptide and each treatment time were summed to obtain the graph above) in the 
ANOVA post hoc test, Bonferroni. 
Titration of treatment by A 0 1-42 
4 5 
g 3 40 
§ -2 _ 
CQ ** *n — _ 
" } « 1 3 5 
s-i.cs 
« 2 ^  
M l 3 0 
<y ~ > 
a v — 
cac X '2 £ 'S. S ^  £ 20 
•2 S e 
s a is a a • -v « 68 s ! 
1 . 5 > 10 
o 
P 68 
E * 5 
Time (min) 
Fig. 21. The amount of hyperphosphorylated tau in differentiated SH-SY5Y cells after a short treatment with Aft 1-
42 and recovery for 24 hours. The neuroblastoma cells were treated with aggregated Aft 1-42 (10 pM) from 0 to 
60 min. After the treatment, the cell culture medium, containing Aft, was removed and the cells were washed with 
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cell culture medium. The living cells were incubated in culture medium for recovery (24 h, 37 °C and 5 % CO2 
without A[3). The fluorescence intensity (measured by immunocytochemistry with FITC-labeled antibody) suddenly 
increased between the A/3 1-42 treatment periods of 10 and 20 min. The fluorescence intensities are equivalent to 
the quantities of hyperphosphorylated tau proteins in the A/3-treated cells. * Differences compared to the untreated 
control values (0 min) are significant at a level p<0.01; n=5 (five histograms for each peptide and each treatment 
time were summed to obtain the graph above) in the ANOVA post hoc test, Bonferroni. 
4.8. Exogenous Afi 1-42 induces oxidative stress in differentiatedSH-SY5Ycells 
Ap 1-42 is known for causing oxidative stress in human neurons (Cutler et al., 2004). 
Figure 23 shows that this process reaches its maximal value in the Ap-treated cells within 3 
hours. (The paraquat was the positive control for the superoxid generation). 
The pentapeptide LPYFDn decreased superoxid generation (Fig. 22, co-treatment with 
Ap 1-42). In another experiment, co-treatment of the cells with Ap 1-42 and pGn resulted in the 
same extent of increase of superoxid level as that due to Ap 1-42 alone (not shown in Fig. 22). 
Fig. 23 shows that the lipid peroxidation increased after 3 hours of Ap 1-42 treatment (oxidated 
form of the fluorescent dye increased and the non oxidated form decreased). 
Time (hour) 
Fig. 22. Increase in the superoxid ( O f ) content in differentiated SH-SY5Y cells caused by aggregated Aft 1-42. 
Oxidative stress was detected with dihydro-ethidine (DHE). Aggregated Af3 1-42 (10 pM) increased the Of 
significantly during the 3 hours after Ap treatment. The superoxid generator paraquat (1 mM) was the positive 
control. The pentapeptide LPYFDn significantly prevents the oxidative stress caused by the aggregated Afi 1-42. * 
The differences in the fluorescence intensity compared with the starting values (1 hour) are significant at a level 
p<0.01. *The fluorescence intensity differences compared to the Afi 1-42 values are significant at a level p<0.01; 
n=5 (five histograms for each peptide and each treatment time were summed to obtain the graph above) in the 
ANOVA post hoc test, Bonferroni. 
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Fig. 23. Increase in the peroxidated lipid content in differentiated SH-SY5Y cells caused by aggregated Aft 1-42. 
Lipid peroxidation was detected with CI 1-BODIPY58"5'". Aggregated A(3 1-42 (10 pM) increased the lipid 
peroxidation (oxydized form) significantly during the 3 hours after A¡3 treatment. Hydrogen-peroxid (H2O2I 100 
pM) was the positive control. * The differences in the fluorescence intensity compared to the non-oxydized form 
are significant at a level p<0.01. *The fluorescence intensity differences compared to the oxidated form (0 hour) 
values are significant at a level p<0.01; n-5 (five histograms for each peptide and each treatment time were 
summed to obtain the graph above) in the ANOVA post hoc test, Bonferroni. 
4.9. Exogenous A(31-42 increases intracellular calcium level in differentiatedSH-SY5Ycells 
Ap 1-42 causes calcium influx in human neurons (Pereira et al., 2004). Figure 25 shows 
that this process reaches its maximal value in the Ap-treated cells within 50 sec. The amyloid 
induced calcium signal reached a continuous value. (Ionomicin was the positive control for the 
calcium influx mechanism). 
The pentapeptide LPYFDn inhibited the calcium influx in the differentiated 
neuroblastoma cells (Fig. 24, co-treatment with Ap 1-42). 
4.10. The inhibitory effect of the A [31-42 on cell attachment 
In our experiments, the Ap 1-42 alone, and the amyloid or fibronectin analog peptides 
(FRHDSn; GRGDSn) inhibited significantly the cell number bound to the surface of the wells. 
(The anti-integrin pi antibody was the positive control). Other amyloid analog peptides (e.g. 
KLVFFn, RIIGLn or LPYFDn) did not inhibit the cell attachment to the surface of the wells 
(Fig. 25). This measurement highlighted the important role of adhesion molecules (ex. 
integrins) in the mechanism of amyloid neurotoxicity. 
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Fig. 24. Increase in the intracellular calcium level ([Ca2+]) in differentiated SH-SY5Y cells caused by aggregated 
Aft 1-42 (10 pM). [Ca2*], was detected with Fura-2 AM (5 pM). Aggregated A/3 1-42 (10 pM) increased the 
[Ca2+]i significantly during the first min after A¡3 treatment. Ionomicin (30 pM) was the positive control. The 
pentapeptide LPYFDn significantly prevented the increase of the [Ca2*], caused by the aggregated A ¡3 1-42. * The 
differences in fluorescence intensity compared to the starting values (0 sec) are significant at a level p<0.01. *The 
fluorescence intensity differences compared to the Afi 1-42 values are significant at a level p<0.01; n=8 in the 
ANOVA post hoc test, Bonferroni. 
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Fig. 25. The inhibitory effect of the Ap 1-42 (10 pM) on cell attachment. The anti-integrin f l antibody (1:100 
dilution) was the positive control. Aggregated Af 1-42, GRGDSn and FRHDSn pentapeptides inhibited the cell 
attachment to the 24 well plate surface. The KLVFFn, RIIGLn and the LPYFDn pentapeptides had no negative 
effect on cell attaching. * Differences compared to the untreated control values are significant at a levelp<0.01, 
n=21. Statistical analysis by ANOVA post hoc test, Bonferroni. 
3 8 
4.11. Kinetic studies of interaction between aggregated A ¡31-42 and LPYFDn 
LPYFDn was found to protect neuroblastoma cells against the toxic effect of A|3 1-42 
aggregates. We also studied the possible interaction between Ap 1-42 and LPYFDn or pGn by 
using the simple CR assay (Fig. 26) in a cell-free system. It is known that Ap 1-42 aggregates 
bind CR (Klunk et ai, 1999), forming salt bridges and H-bonds (Carter et al., 1998; Khurana et 
al., 2001). The amount of CR bound to Ap can be measured spectrophotometrically (A .m ax 550 
nm). It was found that pGn had no effect on the Ap-CR complex (Fig. 26). LPYFDn alone 
cannot be bound to CR. Since incubation of Ap 1-42 with LPYFDn for 5 h decreased the 
amount of Ap-bound CR by 50%, this pentapeptide clearly interacts with Ap 1-42 aggregates. 
24 hours incubation of Ap 1-42 aggregates with LPYFDn, completely prevented the binding of 
CR to AP 1-42 aggregates. 
Figure 28 represents the interaction between AP 1-42 and LPYFDn obtained by computational 
blind docking experiments. [The methodology of blind docking was published in our previous 
studies (Hetenyi et al., 2002a; Hetenyi et al., 2002b).] The 18-22 region (VFFAE) of the Ap 1-
42 might be involved in the interaction with the LPYFDn peptide according to the calculations. 
This finding correlates with the results of Carter et al., where the Ap 16-22 sequence 
(KLVFFAE) proved to be active in binding of Congo red. The common active region (VFFAE) 
of LPYFDn and Congo red is a plausible reason of the decrease of Congo red binding to the 
amyloid peptide in the presence of LPYFDn. 
Fig. 26. The interaction between aggregated A¡3 1-42 and pentapeptide LPYFDn, measured by CR assay. The 
0,4 
aggregated Afi 1-42 (10 pM) was stained by CR (10 pM). The pentapeptide LPYFDn (50 pM) significantly 
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changed the CR binding affinity (incubation time 5 or 24 hours) of the aggregated A fi 1-42. pGn (50 pM) did not 
modify the CR binding affinity to the A ft peptide. 'Optical density differences compared to the positive control A fi 
1-42 values are significant at a levelp<0.01, n=5, in ANOVA post hoc test, Bonferroni. 
Fig. 27. The steric model of binding between A/1 1-42 and LPYFD. The structure of the LPYFDn pentapeptide-
amide (sticks) docked on the surface of the Afl 1-42 molecule. Due to the blind docking study, the V18...E22 
sequence of the f-amyloid molecule is involved in the interaction. 
40 
5. Discussion 
Our results demonstrated that the MTT assay can be used for neurotoxicity studies of 
aggregating peptides, and the application of differentiated cells has many advantages. Ba et al. 
(2003) found similar results on using the cell proliferation reagent WST-1 assay for 
neurotoxicity investigations. Reliable in vitro assays are essential for study of the effects of 
neurotoxic compounds such as P-amyloid peptides. An 8-10 day-treatment of the 
neuroblastoma cells with RA results in a high differentiation grade which is similar to that for 
primary cell cultures. Differentiated cells are both morphologically and physiologically very 
close to living neurons in the brain, therefore the results of neurotoxicity studies are much more 
reliable with differentiated than with non-differentiated cells. A differentiated SH-SY5Y cell is 
a good in vitro "neuron-model". Correction of the results is not necessary in consequence of the 
constant cell number in the differentiated cell culture. 
We set out to study the early events of neurite degeneration and the intracellular changes 
caused by Ap 1-42 aggregates in the differentiated SH-SY5Y neuroblastoma cell line (Fig. 28). 
We used in all experiments fibrillar Ap 1-42. Light microscopical examination (Fig. 12) shows 
that severe morphological changes occur during the first 60 min: AP 1-42 clusters bind to the 
cells and cause the degeneration of the neurites and the contraction (rounding-off) of the 
perikaryon. The degeneration becomes more severe as time passes. The light microscope 
proved to be a useful tool for the study of neurodegeneration. Obviously, scanning electron 
microscopy furnishes more information: Ap 1-42 forms large spherical clusters with diameters 
up to 2 pm (Fig. 9/A2), and these clusters bind to the cell surface. Direct measurement of Ap 1-
42 aggregates by using the CR method (Fig. 17) and immunocytochemistry (Fig. 18/A/B) 
indicated that the amount of cell-bound Ap 1-42 steadily increased during the first 60 min (Fig. 
17). The concentration of CR correlates with the amount of aggregated Ap 1-42. We suppose 
that the primary factor, which mediates the effects of Ap 1-42, is the amount of the peptide 
bound to the membranes. Further experiments with specific antibodies and quantitative 
measurement of hyperphosphorylated tau proteins proved that Ap 1-42 aggregates give rise to a 
significant increase within a short time (20 min). The amount of hyperphosphorylated tau 
proteins reaches its maximum in 30 min (Fig. 20). This hyperphosphorylation is reversible if 
the treatment with Ap 1-42 is relatively short (2 to 10 min), but it becomes irreversible after 20 
min (Fig. 21). The release of hyperphosphorylated tau results in decomposition of the 
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microtubular system (Fig. 18/C/D); if the hyperphosphorylated tau proteins form aggregates 
(paired helical filaments; Torreilles et al., 2002), the decomposition is irreversible. Intracellular 
tau aggregation is also a time-dependent process, this might be the explanation of the time 
dependence of the cytoskeletal deorganization caused by Ap 1-42 (Grace et al., 2002; 2003). 
The study of the neurotoxicity of A(3 1-42 by the means of MTT assay (cellular redox 
activity) and Neutral Red assay (active membrane uptake) provided another evidence of the 
time dependence of irreversibility (Fig. 16). The treatment of the cells with Ap 1-42 led to an 
irreversible decrease in cell viability after very short time (2 min). Although the tau 
hyperphosphorylation becomes irreversible only after a longer period (more than 10 min), other 
changes in cell viability (e.g. factors involved in generating the redox potential of the cell) are 
irreversible within a short period of time. (The MTT assay measures the result of very complex 
processes in which reduced coenzymes and ATP are formed; Liu et al., 1997a; 1997b.) Rapid 
deterioration of the cell viability (superoxid generation, Fig. 22; lipid peroxidation, Fig. 23; 
increase of the intracellular calcium level, Fig. 24) and destruction of the cytoskeletal elements 
together induce changes in cell morphology (neurite degeneration) in the neuroblastoma 
culture. Similar processes might be responsible for the in vivo neuronal degeneration (Brandt, 
2001; Hamdane et al., 2003). In our experiments, 2 to 10 min contact of Ap 1-42 aggregates 
(10 pM) with neuroblastoma cells caused irreversible changes. 
The mechanism of amyloid neurotoxicity in part is mediated by activation and 
clusterization of the adhesion molecules (ex. integrins; Grace et al., 2002; 2003 and Cotman et 
al., 1998). AP aggregates inhibited cell attachment to the extracellular matrix (wells surface) 
similarly with integrin like antibody and the fibronectin analog RGD peptides (Fig. 25). 
Some short Ap-sequences are known as p-sheet breakers (BSBs; Tjernberg et al., 1996; 
Soto et al., 1998). The pentapeptide LPYFDn was designed on the basis of Soto's well-known 
BSB-peptide LPFFD. In order to increase the binding force to Ap peptides, two changes in the 
structure were performed: 1) one phenylalanine was replaced with tyrosine: the additional 
phenolic OH-group increases the binding affinity; 2) the C-terminal carboxylate anion (-COO") 
was replaced with carboxamide (-CONH2) group to increase the binding affinity according to 
quantum chemical calculations (AutoDock). The new peptide, LPYFDn, has a very high 
binding affinity to AP-fibrils. This peptide proved to be an excellent inhibitor of the neurotoxic 
events triggered by Ap 1-42 aggregates and almost completely prevented oxidative stress (Fig. 
22 and 23), the increase of the intracellular calcium level (Fig. 24) and the tau 
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hyperphosphorylation caused by Ap 1-42 (Fig. 20). In the MTT assay, LPYFDn in 5-fold molar 
excess prevented the neurotoxic effect of Ap 1-42 (pGn was ineffective in this test; Fig. 15). 
The pGn peptide was used because it does not have side chain groups and any determined 
conformation so it has practically no binding affinity to protein surfaces. LPYFDn partly 
prevented the binding of Ap 1-42 clusters to SH-SY5Y cells and neurite degeneration, both 
after 5 min and/or after 12 hours co-aggregation with Ap 1-42 (Fig. 13). 
Aggregated Aß 1-42 
A AAAAAAl • • • • • • • ¡1 y ,i«rww y PEROXIDATION » y u u u u u u u u y y y i 
J r [Ca21i T 4 
PROTEIN KINASE HYPERPHOSPHORYLATION / CLUSTERIZATION 
ACTIVATION • • • 
APOPTOSIS? 
CYTOSKELETON 
TAU AGGREGATION PHF NT CELL and NEURITE PLASTICITY 
INTRACELLULAR TRANSPORT DEFECTS 
NEURITE DEGENERATION 2 h) 
OXIDATIVE STRESS 
CELL MIGRATION 
APOPTOSIS? 
CROSS-LINKING of 
NMD A, nAChR, 
G-prntein, 
Na+/K+ 
INTE GRINs, Ig-SF 
(+NCAM, ICAM, 
p RAGE, APP) p 
Fig. 28. Hypothetic mechanism of the in vitro neurotoxicity of the aggregated Aft 1-42 peptide in differentiated SH-
SY5Y neuroblastoma cells. Aggregated Aft 1-42 cause: protein kinase activation, hyperphosphorylation, 
clusterization of the adhesion molecules and lipid peroxidation. The protein kinase activation alone is not enough 
for the induction of the apoptotic cascade. Hyperphosphorylation and clusterization together cause the collapse of 
the cytoskeleton (intracellular transport defects, neurite degeneration). The normal functions of the cytoskeleton 
(cell plasticity, cell migration) are damaged. 
The mechanism of the neuroprotective effect of our pentapeptides is not perfectly clear. 
In a cell-free experiment, LPYFDn competes with CR for the binding sites of the Ap surface, 
and after co-aggregation of Ap 1-42 and LPYFDn for 24 h, no CR binding can be observed. 
43 
The co-aggregation of pGn with Ap 1-42 causes practically no change in CR binding (Fig. 26). 
Interestingly, LPYFDn can not prevent the formation of AP fibrils and spherical clusters; the 
amount of Ap aggregates remains unchanged after LPYFDn treatment. Electron microscopic 
studies also demonstrate that the co-aggregation of Ap with LPYFDn for 1 to 3 days does not 
disturb fibril formation (to be published elsewhere). Molecular simulation (AutoDock) 
calculations reveal that LPYFDn can be tightly bound to the surface of Ap 1-42 (Hetenyi et al., 
2002a; Hetenyi et al, 2002b; Fig. 27). We presume that the pentapeptide LPYFDn (and perhaps 
also other short Ap peptides) binds to the surface of Ap aggregates, thereby preventing the 
interaction of Ap 1-42 clusters with the membrane proteins of the neurons. The degree of 
polymerization and the fibrillar structure of Ap 1-42 may remain unchanged, but the surface is 
covered with short peptide fragments, amyloid surface covering molecules (ASCOM) that 
prevent cell adhesion and neurotoxicity. These short protective peptides could be beneficial for 
the therapeutic treatment of AD (Soto et al., 1998; 2000; Sigurdsson et al., 2000). Further 
studies are necessary to explain the exact neuroprotective mechanism of short peptides. 
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6. Summary 
Many neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's 
disease, amyotrophic lateral sclerosis, prion- and Huntington's disease are characterized by 
neural damage that may be caused by toxic, abnormal, aggregation-prone-proteins. The 
mechanism of AD specific neurodegeneration is not clearly understood yet. Since investigation 
of any biochemical and cell-physiological events are impossible in AD human brain, monkey, 
rat or mouse models are used which are more similar to human specific neurodegenerative 
events than in vitro cell culture models. However, owing to high expenses and timing, I used in 
vitro methods instead of in vivo ones. In addition, screening of drug candidates at the early 
stage of research need fast in vitro cell culture methodologies. My research field also involves 
the in vitro modelling of the Alzheimer's disease specific neurodegeneration and 
neuroprotection in cell cultures. 
Different methods were used to investigate the mechanism of action of Ap peptides on 
neuroblastoma cells: viability assays, fluorescence microscopy, confocal and transmission 
electron microscopy, immunocytochemistry. 
Our results: 
1. We worked out a neurotoxicity assay using fully differentiated SH-SY5Y human derived 
neuroblastoma cells; 
2. The in vitro results correspond to the markers which are characteristic of AD. These markers 
are the following: neurite degeneration, oxidative stress, increase of the intracellular calcium 
level, tau hyperphosphorylation and collapse of cytoskeleton after the Ap or NAC treatment; 
3. AD can be modelled by the mutual use of full-differentiated human neuroblastoma cell 
culture and aggregated (diffusible or fibrillar) polypeptides such as Ap and NAC; 
4. Aggregated Ap 1-42 induced irreversible changes in the neurite morphology. Changes in cell 
viability and physiology are irreversible during the first hour after the addition of Ap 1-42 to the 
cells. These rapid events indicate that Ap might induce neurodegeneration even at an early 
stage of the Ap - cell contact; 
5. We have shown that the novel pentapeptide, LPYFDn, an analog of Soto's LPFFD, 
significantly decreased the neurotoxic effect (cell viability reduction) induced by Ap 1-42. This 
pentapeptide blocks the deleterious effects of the Ap 1-42; 
6. These results suggest that peptidomimetic derivatives of LPYFDn (patent 2005) can be 
possible new drug candidates preventing Alzheimer's disease. 
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